U.S. drug prices are nearly four times higher than the combined average price for 11 other similar countries, according to a report released today by the House Ways and Means Committee. Committee staff analyzed 2018 pricing data for 79 drugs sold in the U.S., United Kingdom, Japan, Canada (Ontario), Australia, Portugal, France, the Netherlands, Germany, Denmark, Sweden and Switzerland. “With one exception, we found that individual drug prices in the U.S. ranged from 70% (Lantus Solostar – a type of insulin) to 4,833% (Dulera – a prescription asthma medication) higher than the combined mean price in the other 11 countries,” the report states. “Compared to individual countries, drug prices in the U.S. ranged from 0.6 to 67 times the price for the same drugs.”

Related News Articles

Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…